¸Îϸ°ûÉú³¤Òò×Ó»ùÒòC57488A¶à̬ÐÔÓëÔ·¢ÐÔ¸ßѪѹµÄ¹ØÏµ*¡ï
ÿ
ÃÏ Ó°£¬Íõ°îÄþ
Ó¦ÓÃÒªµã£ºÊÔÑé¹Û²ìÁ˸Îϸ°ûÉú³¤Òò×ӵĵ¥ºËÜÕËá¶à̬ÐÔ·Ö²¼Óë¸ßѪѹ·¢²¡µÄ¹ØÏµ£¬¶øµ¥ºËÜÕËá¶à̬ÐÔ×÷ΪһÖÖ·Ö²¼¹ã·º¡¢ÒÅ´«Îȶ¨µÄ»ùÒòÒÅ´«±ê¼Ç£¬Äܳä·ÖµØ·´Ó³¸öÌå¼äµÄÒÅ´«²îÒ졣ͨ¹ý±¾¿ÎÌâµÄ¹Û²ì½á¹û¿ÉÄÜÔ¤²âºÏ·ÊµØÇøºº×åÈËȺ¸ßѪѹµÄ·¢²¡Çé¿ö£¬¼°ÔçÌá¸ßÔ¤²âÇàÉÙÄê·¢Éú¸ßѪѹµÄ¼¸ÂÊ¡£
ÊõÓï½âÎö£ºµ¥ºËÜÕËá¶à̬ÐÔÖ÷ÒªÊÇÖ¸ÔÚ»ùÒò×éˮƽÉÏÓɵ¥¸öºËÜÕËáµÄ±äÒìËùÒýÆðµÄDNAÐòÁжà̬ÐÔ¡£ÆµÂÊ´óÓÚ1%¡£ËüÊÇÈËÀà¿ÉÒÅ´«µÄ±äÒìÖÐ×î³£¼ûµÄÒ»ÖÖ¡£µ¥ºËÜÕËá¶à̬ÐÔÔÚÈËÀà»ùÒò×éÖй㷺´æÔÚ£¬Æ½¾ùÿ500~1 000¸ö¼î»ù¶ÔÖоÍÓÐ1¸ö£¬¹À¼ÆÆä×ÜÊý¿É´ï300Íò¸öÉõÖÁ¸ü¶à¡£
Æ«Òлò²»×㣺¢ÙÔÚÊÔÑéµÄÉè¼ÆÉÏ£¬Ö»Êǵ¥´¿·ÖÎöÁ˸Îϸ°ûÉú³¤Òò×ӵĵ¥ºËÜÕËá¶à̬ÐÔÓë¸ßѪѹ·¢²¡¼äµÄ¿ÉÄܹØÏµ£¬Î´ÄÜÁªºÏÑо¿Ñª¸Îϸ°ûÉú³¤Òò×ÓˮƽºÍµ¥ºËÜÕËá¶à̬ÐÔ·Ö²¼µÄ¹ØÏµ£¬¶ø½øÒ»²½·ÖÎö̽ÌÖѪ¸Îϸ°ûÉú³¤Òò×Óˮƽ¾ßÌåÊÜÄÄЩµ¥ºËÜÕËá¶à̬ÐÔÓ°Ïì¡£¢Ú±¾ÊÔÑé²ÉÓõķ½·¨½ÏΪ¼òµ¥£¬½ö¹Û²ìÁ˸Îϸ°ûÉú³¤Òò×ÓµÄÒ»¸öµ¥ºËÜÕËá¶à̬ÐÔλµã£¬Í¬Ê±ÊÔÑé¶ÔÏóÊýÄ¿ÒàÆ«ÉÙ¡£
°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÐÄÄÚ¿Æ1²¡Çø£¬°²»ÕÊ¡ºÏ·ÊÊÐ 230022
ÃÏ Ó°¡ï£¬Å®£¬1982ÄêÉú£¬°²»ÕÊ¡¸·ÄÏÏØÈË£¬ºº×壬°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÐÄÄÚ¿ÆÔÚ¶Á˶ʿ£¬Ö÷Òª´ÓʸßѪѹ²¡µÄ»ùÒòÑо¿¡£
mengying1010@
sohu.com
ͨѶ×÷ÕߣºÍõ°îÄþ£¬Ö÷ÈÎҽʦ£¬½ÌÊÚ£¬°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÐÄÄÚ¿Æ1²¡Çø£¬°²»ÕÊ¡ºÏ·ÊÊÐ
230022
wangbangning@
medmail.com.cn
°²»ÕÊ¡¿Æ¼¼¹¥¹Ø¼Æ»®ÏîÄ¿(06013129B)*
ÕªÒª
Ä¿µÄ:Ѫ¹ÜÄÚÆ¤Ï¸°û¹¦Äܲ»È«ÔÚ¸ßѪѹ»¼ÕßÖÐÆÕ±é´æÔÚ£¬¸Îϸ°ûÉú³¤Òò×ÓÔÚÄÚÆ¤Ï¸°û¹¦Äܲ»È«ÖÐÆðÖØÒª×÷Óã¬Óë¸ßѪѹµÄÁ÷ÐС¢ÑÏÖØ³Ì¶È¡¢°ÐÆ÷¹ÙÊÜËðµÈÓйء£Ì½ÌÖ¸Îϸ°ûÉú³¤Òò×Ó»ùÒòC57488AµÄ¶à̬ÐÔÔÚÔ·¢ÐÔ¸ßѪѹ·¢²¡»úÖÆÖеÄ×÷Óá£
·½·¨£º¢ÙÊÔÑé¶ÔÏó£ºÑ¡Ôñ2006-06/12ÔÚ±¾Ôº±£½¡ÖÐÐÄÌå¼ì»ò±¾¿ÆÊÒסԺµÄÔ·¢ÐÔ¸ßѪѹ»¼Õß¹²107Àý×÷ΪԷ¢ÐÔ¸ßѪѹ×飬ƽ¾ùÄêÁ䣨61¡À9£©Ë꣬ÆäÖÐÓиßѪѹ¼Ò×åÊ·Õß¹²47Àý£»ËùÓжÔÏó¾ùΪºÏ·ÊµØÇø¾ÓסÇÒÎÞѪԵ¹ØÏµµÄºº×åÈË£¬»¼Õß¶ÔÊÔÑéÖªÇéͬÒ⣬ÊÔÑé¾Ò½ÔºÒ½Ñ§Â×ÀíίԱ»áÅú×¼¡£²¡ÀýÊÕ¼¯°´ÕÕÖлªÒ½Ñ§»áÖÆ¶©µÄ¸ßѪѹָÄϱê×¼£¬ÊÕËõѹ¡Ý140 mm Hg£¬»òÊæÕÅѹ¡Ý 90 mm Hg (1 mm Hg=0.133 kPa)£¬»òÃ÷È·Õï¶ÏΪ¸ßѪѹ¶ø½ÓÊÜÒ©ÎïÖÎÁÆ´ï1ÄêÒÔÉÏÕß¡£1¸öÔÂÄÚ½ö·þÓýµÑ¹Ò©¡£Í¬Ê±Ñ¡ÔñÎ´Ôø½ÓÊܸßѪѹҩÎïÖÎÁƵĽ¡¿µÈ˹²110Ãû×÷ΪÕý³£¶ÔÕÕ×飬ƽ¾ùÄêÁ䣨60¡À8£©ËꣻÄÉÈë±ê×¼£ºÊÕËõѹ< 140 mm Hg£¬ÊæÕÅѹ< 90 mm Hg£¬²¢Åųý¸ßѪѹ¼Ò×åÊ·¡£ËùÓÐÊÜÊÔ¶ÔÏó¾ùÏêϸµ÷²é¼Ò×åÊ·£¬Åųý¼Ì·¢ÐÔ¸ßѪѹ¡¢ÌÇÄò²¡¡¢¹ÚÐIJ¡¡¢¼××´ÏÙ¼²²¡¡¢ÑÏÖØµÄ¸ÎÉö¼²²¡¼°Ðķι¦Äܲ»È«µÈ¡£¢ÚÊÔÑé·½·¨¼°ÆÀ¹À£ºËùÓÐÊÜÊÔ¶ÔÏó¾ù²â¶¨ÑªÑ¹¡¢Éí¸ß¡¢ÌåÖÊÁ¿£¬¼ÆËã³öÌåÖÊÁ¿Ö¸Êý£¬³£¹æÉú»¯²â¶¨×ܵ¨¹Ì´¼¡¢Èýõ£¸ÊÓÍ¡¢¼«µÍÃܶÈÖ¬µ°°×¡¢¿Õ¸¹ÑªÌǵȡ£²ÉÓõ¥Ò»µÈλ»ùÒòÌØÒìÐÔÒýÎïPCR¼¼Êõ²â¶¨Á½×é¸Îϸ°ûÉú³¤Òò×ӵĻùÒòÐͼ°¸Îϸ°ûÉú³¤Òò×ÓC57488A»ùÒò¶à̬ÐÔ·Ö²¼¡¢¸÷»ùÒòÐͺ͵Èλ»ùÒòƵÂÊ·Ö²¼¡£
½á¹û£ºÄÉÈëÔ·¢ÐÔ¸ßѪѹ»¼Õß107ÀýºÍ½¡¿µÈË110Ãû£¬¾ù½øÈë½á¹û·ÖÎö¡£¢ÙÔ·¢ÐÔ¸ßѪѹ×éºÍÕý³£¶ÔÕÕ×éµÄÄêÁä¡¢ÐÔ±ð¡¢ÌåÖÊÁ¿Ö¸Êý¡¢Èýõ£¸ÊÓÍ¡¢×ܵ¨¹Ì´¼¡¢¼«µÍÃܶÈÖ¬µ°°×ºÍ¿Õ¸¹ÑªÌDzîÒì¾ùÎÞÏÔÖøÐÔ(P > 0.05)¡£¢ÚËùÓÐÊÜÊÔ¶ÔÏó»ùÒò¶à̬ÐÔ·Ö²¼·ûºÏHardy-Weinbergƽºâ£¬¾ßÓÐȺÌå´ú±íÐÔ¡£Ô·¢ÐÔ¸ßѪѹ×éÖÐÓмÒ×åÊ·Õß(47Àý)ºÍÎÞ¼Ò×åÊ·Õß(60Àý)µÄCC¡¢CA¡¢AA»ùÒòÐÍÆµÂÊ·Ö±ðΪ0.809¡¢0.170¡¢0.021ºÍ0.733¡¢0.233¡¢0.033£¬C¡¢AµÈλ»ùÒòƵÂÊ·Ö±ðΪ0.894¡¢0.106ºÍ0.850¡¢0.150¡£Õý³£¶ÔÕÕ×é¸Îϸ°ûÉú³¤Òò×Ó»ùÒòC57488A µÄCC¡¢CA¡¢AA»ùÒòÐÍÆµÂÊ·Ö±ðΪ0.527¡¢0.355¡¢0.060£»C¡¢AµÈλ»ùÒòƵÂÊ·Ö±ðΪ0.705¡¢0.295¡£¢ÛÔ·¢ÐÔ¸ßѪѹ×éÖÐÓмÒ×åÊ·ºÍÎÞ¼Ò×åÊ·Õß»ùÒòÐÍCCºÍµÈλ»ùÒòCƵÂʾù¸ßÓÚÕý³£¶ÔÕÕ×é(P < 0.01£¬P < 0.05)£»ÓмÒ×åÊ·ÕßCC»ùÒòÐÍÆµÂʺÍCµÈλ»ùÒòƵÂʾù¸ßÓÚÎÞ¼Ò×åÊ·Õߣ¬µ«²îÒìÎÞÏÔÖøÐÔ (P > 0.05)¡£
½áÂÛ£ººÏ·ÊµØÇøºº×åÈËȺԷ¢ÐÔ¸ßѪѹµÄ·¢ÉúÓë¸Îϸ°ûÉú³¤Òò×Ó»ùÒòC57488A¶à̬ÐÔÓйأ¬»ùÒòÐÍCCºÍµÈλ»ùÒòC¿ÉÄÜÊÇÔ·¢ÐÔ¸ßѪѹµÄÒ׸ÐÒòËØ¡£
¹Ø¼ü´Ê£º¸Îϸ°ûÉú³¤Òò×Ó£»Ô·¢ÐÔ¸ßѪѹ£»»ùÒò¶à̬ÐÔ
ÃÏÓ°£¬Íõ°îÄþ.¸Îϸ°ûÉú³¤Òò×Ó»ùÒòC57488A¶à̬ÐÔÓëÔ·¢ÐÔ¸ßѪѹµÄ¹ØÏµ[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(11):2043-2046 [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2043(ps).pdf]
ÖÐͼ·ÖÀàºÅ:R392.114
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)11-02043-04
ÊÕ¸åÈÕÆÚ£º2007-09-06
ÐÞ»ØÈÕÆÚ£º2007-11-16
(07-50-8-4431/WL¡¤Y)
Hepatocyte growth factor gene C57488A polymorphism and essential hypertension
Abstract
AIM:The impaired function of vascular endothelial cells occurs popularly in hypertensive patients. Hepatocyte growth factor (HGF) plays a crucial role on impaired function, and is related to prevalence, severity and target organ damages of hypertension. This study explored the relationship between HGF gene C57488A polymorphism and essential hypertension (EH).
METHODS: ¢ÙBetween June and December in 2006, totally 107 EH patients with an average age of (61¡À9) years, in them 47 cases with family history of hypertension, were recruited in this study. Informed consents were obtained from the patients who were all the Han residents of Hefei area, and the experiment was approved by the hospital ethical committee. The hypertension criteria formulated by Chinese Medical Association included the systolic pressure ¡Ý140 mm Hg or diastolic pressure ¡Ý 90 mm Hg (1 mm Hg=0.133 kPa), or having received drug therapy for hypertension over one year. The patients were administrated with hypotensive drugs with one month. Meanwhile 110 normotensives without family history of hypertension and drug therapy were served as controls, with an average age of (60¡À8) years. Inclusion criteria: systolic pressure < 140 mm Hg or diastolic pressure < 90 mm Hg (1 mm Hg=0.133 kPa). All the subjects were surveyed for family history, excluding secondary hypertension, diabetes, coronary heart disease, thyroid disease, severe liver and kidney disease, cardiorespiratory function insufficiency and so on.¢ÚDetection parameters included blood pressure, height, weight, body mass index, and total cholesterol, triacylglycerol, very low density lipoprotein, fasting blood glucose were detected biochemically. Single allele-special primer polymerase chain reaction technique was used to examine the polymorphism of HGF genetypes and distribution of allele frequency in two groups.
RESULTS: Both 107 EH patients and 110 healthy controls were involved in the result analysis.¢ÙThere were no significant differences in age, sex, body mass index, total cholesterol, triacylglycerol, very low density lipoprotein and fasting blood glucose between the EH group and the controls (P > 0.05).¢ÚThe distributions of HGF gene C57488A polymorphism were in agreement with Hardy-Weinberg equilibrium, indicating population representativeness. The frequencies of three genotypes CC, CA, AA were 0.809, 0.170, 0.021 and C, A alleles were 0.894, 0.106 in the EH group with family history respectively. Correspondingly, the frequencies were 0.733, 0.233, 0.033 and 0.850, 0.150 respectively in the EH patients without family history. Meanwhile, the frequencies were 0.527, 0.355, 0.060 and 0.705, 0.295 respectively in the controls.¢ÛThe frequencies of genotype CC and allele C were both significant higher in EH with or without family history compared with the controls (P < 0.01, P < 0.05), but no significant difference was observed between the EH with family history and those without family history (P > 0.05).
CONCLUSION: HGF gene C57488A polymorphism is possibly associated with EH, and genotype CC and allele C may be the factors of genetic predisposition of EH in Han population of Hefei area.
Meng Y, Wang BN.Hepatocyte growth factor gene C57488A polymorphism and essential hypertension.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(11):2043-2046(China)
[www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2043(ps).pdf]
0 ÒýÑÔ
Ô·¢ÐÔ¸ßѪѹ£¨Essential hypertension, EH£©ÊÇÒ»ÖÖÓÉÒÅ´«ÒòËØºÍ»·¾³ÒòËØÏ໥×÷ÓõĶà»ùÒòÒÅ´«ÐÔ¼²²¡£¬ÆäÖлùÒòÔÚ¸ßѪѹµÄ·¢²¡ÖÐÆð30%µÄ×÷ÓÃ[1]£¬Ñ°ÕÒÓëEHÏà¹ØµÄÒ׸лùÒò¡¢²ûÃ÷EH·¢²¡µÄÒÅ´«»úÖÆÒѾ³ÉΪĿǰÑо¿µÄÈȵ㡣ÈÏΪֻҪ»ùÒò±àÂëµÄµ°°×ÖʲÎÓëÁËѪѹµ÷½Ú»úÖÆ£¬¸Ã»ùÒò¾Í¿ÉÒÔ×÷ΪEHµÄºòÑ¡»ùÒò[2]¡£Ä¿Ç°²ÎÓëѪѹµ÷½Ú»úÖÆÖ÷ÒªÓÐÒÔϼ¸¸öϵͳ£ºÉöËØ-Ѫ¹Ü½ôÕÅËØ-È©¹Ìͪϵͳ£¬¼¤ëÄÊÍ·Åø-¼¤ëÄϵͳ£¬¶ù²è·Ó°·/ÉöÉÏÏÙËØÄÜϵͳ£¬ÄÆÍ¨µÀÒì³££¬ÄÚÆ¤¹¦Äܲ»È«¼°ÒȵºËصֿ¹µÈ¡£¹ØÓÚÒÔÉÏ´ó¶àϵͳÎïÖÊ»ùÒòÓëEH¹ØÏµÑо¿ÒѾÂżû±¨µÀ[3-7]¡£¶øÆäÖÐѪ¹ÜÄÚÆ¤Ï¸°û¹¦Äܲ»È«ÔÚ¸ßѪѹ»¼ÕßÖÐÆÕ±é´æÔÚ£¬ÔÚ¸ßѪѹµÄ·¢²¡»úÖÆÖаçÑÝÖØÒª×÷Óᣠ¸Îϸ°ûÉú³¤Òò×Ó£¨Hepatocyte growth factor£¬HGF£©ÊÇÒ»ÖÖ¼äÖÊÀ´Ô´µÄ¶àÔ´ÐÔÒò×Ó£¬½üÄêÀ´Ô½À´Ô½¶àµÄÑо¿±íÃ÷ÆäÔÚÄÚÆ¤Ï¸°û¹¦Äܲ»È«ÖÐÆðÖØÒª×÷ÓÃ[8]£¬Óë¸ßѪѹµÄÁ÷ÐС¢ÑÏÖØ³Ì¶È¡¢°ÐÆ÷¹ÙÊÜËðµÈÓйØ[9]¡£¶ø¹ØÓÚHGFµÄ»ùÒòµ¥ºËÜÕËá¶à̬ÐÔÓë¸ßѪѹ¹ØÏµµÄÑо¿¾¼ìË÷Íò·½Êý¾Ý¿âδ¼û±¨µÀ£¬±¾¿ÎÌâ¾Í´Ë×÷Ò»Ñо¿¡£
1 ¶ÔÏóºÍ·½·¨
Éè¼Æ£º²¡Àý-¶ÔÕչ۲졣
µ¥Î»£º°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÐÄÄÚ¿Æ1²¡Çø¡£
¶ÔÏó£ºÑ¡Ôñ2006-06/12ÔÚ±¾Ôº±£½¡ÖÐÐÄÌå¼ì»ò±¾¿ÆÊÒסԺµÄEH»¼Õß¹²107Àý×÷ΪEH×飬ÄÐ64Àý£¬Å®43Àý£¬Æ½¾ùÄêÁä(61¡À9)ËꣻÆäÖÐÓиßѪѹ¼Ò×åÊ·Õß¹²47Àý£¬ÄÐ28Àý£¬Å®19Àý£»°´ÕÕÖлªÒ½Ñ§»áÖÆ¶©µÄ¸ßѪѹָÄϱê×¼£¬ÊÕËõѹ¡Ý140 mm Hg£¬»òÊæÕÅѹ¡Ý 90 mm Hg (1 mm Hg = 0.133 kPa)£¬»òÃ÷È·Õï¶ÏΪ¸ßѪѹ¶ø½ÓÊÜÒ©ÎïÖÎÁÆ´ï1ÄêÒÔÉÏÕß¡£1¸öÔÂÄÚ½ö·þÓýµÑ¹Ò©¡£Í¬Ê±Ñ¡ÔñÎ´Ôø½ÓÊܸßѪѹҩÎïÖÎÁƵĽ¡¿µÈ˹²110Ãû×÷ΪÕý³£¶ÔÕÕ×飬ÄÐ68Àý£¬Å®42Àý£¬Æ½¾ùÄêÁ䣨60¡À8£©ËꣻÄÉÈë±ê×¼£ºÊÕËõѹ< 140 mm Hg£¬ÊæÕÅѹ< 90 mm Hg£¬²¢Åųý¸ßѪѹ¼Ò×åÊ·¡£ËùÓÐÊÜÊÔ¶ÔÏó¾ùÏêϸµ÷²é¼Ò×åÊ·£¬ÓиßѪѹ¼Ò×åÊ·ÊÇÖ¸Æä¸¸Ä¸ÖÁÉÙ1ÈË»òֱϵÇ×ÊôÖÐÓÐ1¸öÈËÒÔÉÏ»¼EH¡£ËùÓй۲ì¶ÔÏó¾ùÅųý¼Ì·¢ÐÔ¸ßѪѹ¡¢ÌÇÄò²¡¡¢¹ÚÐIJ¡¡¢¼××´ÏÙ¼²²¡¡¢ÑÏÖØµÄ¸ÎÉö¼²²¡¼°Ðķι¦Äܲ»È«µÈ¡£±¾ÊÔÑé¾Ò½ÔºÒ½Ñ§Â×ÀíίԱ»áÅú×¼£¬»¼Õß¶ÔÊÔÑéÖªÇéͬÒ⣬ËùÓжÔÏó¾ùΪºÏ·ÊµØÇø¾ÓסÇÒÎÞѪԵ¹ØÏµµÄºº×åÈË¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÊÔÑéÉè¼ÆÎªµÚÒ»¡¢¶þ×÷Õߣ¬¸ÉԤʵʩΪµÚÒ»×÷Õߣ¬ÆÀ¹ÀΪµÚ¶þ×÷Õß¡£¾¹ýÕý¹æÅàѵ£¬²ÉÓÃä·¨ÆÀ¹À¡£
·½·¨£º
ÁÙ´²Ö¸±êµÄ²â¶¨£ºËùÓÐÊÜÊÔ¶ÔÏó¾ù²â¶¨ÑªÑ¹¡¢Éí¸ß¡¢ÌåÖÊÁ¿£¬¼ÆËã³öÌåÖÊÁ¿Ö¸Êý£¬³£¹æÉú»¯²â¶¨×ܵ¨¹Ì´¼¡¢Èýõ£¸ÊÓÍ¡¢¼«µÍÃܶÈÖ¬µ°°×¡¢¿Õ¸¹ÑªÌǵȡ£
DNAÌáÈ¡£ºEDTA¿¹ÄýÍâÖܾ²ÂöȫѪ 1 mL£¬ÓÃȫѪDNAÊÔ¼ÁºÐ·¨£¨¹ºÓÚÉϺ£Èü°ÙÊ¢ÉúÎ﹤³ÌÓÐÏÞ¹«Ë¾£©³éÌá»ùÒò×éDNA¡£
HGF»ùÒòSNP¼ì²â£º¢Ùͨ¹ýÃÀ¹úNCBI£¨ÃÀ¹ú¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©µÄgene bank»ñÈ¡HGFÐòÁм°C57488AµÄSNPÐÅÏ¢(rs2074725)¡£ÀûÓÃPrime 5.0ºÍOligo 6.53×ÔÐÐÉè¼ÆÒýÎï¡£ÒýÎïÓÉÉϺ£ÉúÎ﹤³Ì¼¼ÊõÓÐÏÞ¹«Ë¾ºÏ³É¡£¢ÚÀûÓõ¥Ò»µÈλ»ùÒòÌØÒìÐÔÒýÎïPCR (Single allel-special primer PCR£¬SASP-PCR)¼¼Êõ¼ì²âHGF»ùÒòC57488AµÄ»ùÒòÐÍ[10]¡£ÒýÎïÐòÁÐÈçÏ£ºHGFÉÏÓÎÒýÎP1-C£¨Ò°ÉúÐÍ£©£º5¡¯-CAA ATT ATA GTC CAG AGC TTA CC-3¡¯£¬P1-A£¨Í»±äÐÍ£©£º5¡¯-CAA ATT ATA GTC CAG AGC TTA CA-3¡¯£»HGFÏÂÓÎÒýÎP2£º5¡¯-TCT TGT GCC
AAA ACG AAA C-3¡¯¡£ÔÀí¼ûͼ1¡£¢ÛPCR·´Ó¦£ºÃ¿¼ìÑéÒ»ÀýÑо¿¶ÔÏóµÄ»ùÒòÐÍ·Ö±ðÐèÒª½øÐÐÁ½¸öPCR·´Ó¦£¬ÆäÖÐÒ»¸ö¹ÜÖмÓP1-C£¬ÁíÒ»¸ö¼ÓP1-A£¬ÆäÓà¾ùÏàͬ¡£ÈçÏÂËùʾ£º×ÜÌå»ý20 ¦ÌL£º10¡ÁBuffer 2 ¦ÌL£¬dNTP 1 ¦ÌL£¬Taqø 0.2 ¦ÌL£¬Primers¸÷1 ¦ÌL£¬DNAÄ£°å1.5 ¦ÌL£¬MgCl2 1.5 ¦ÌL£¬ÎÞ¾úË®11.8 ¦ÌL£¬¶ÌÔÝÀëÐĺóPCRÀ©Ôö¡£PCR²ÎÊý£º94 ¡æ Ô¤±äÐÔ5 min£¬94 ¡æ ±äÐÔ40 s£¬56 ¡æ ÍË»ð40 s£¬72 ¡æ ÑÓÉì1 min£¬Ñ»·35´Î£¬72 ¡æ ÑÓÉì10 min£¬4 ¡æ ´æ·Å±¸¼ì¡£À©ÔöÎïÓÃ1.7%ÇíÖ¬ÌÇÄý½ºµçÓ¾£¬EBȾɫ£¬×ÏÍâ¹âϼì²âµçÓ¾½á¹û¡£
PCR½á¹ûÅжÁ£ºÈôP1-CÓëP2ΪÑôÐÔ£¬P1-AÓëP2ΪÑôÐÔ£¬Ôò»ùÒòÐÍΪCA£»ÈôP1-CÓëP2ΪÒõÐÔ£¬P1-AÓëP2ΪÑôÐÔ£¬Ôò»ùÒòÐÍΪAA£»ÈôP1-CÓëP2ΪÑôÐÔ£¬P1-AÓëP2ΪÒõÐÔ£¬Ôò»ùÒòÐÍΪCC£¨ÑôÐÔΪPCRºóµçÓ¾½á¹û¼ûµ½Ä¿µÄÌõ´ø£¬ÒõÐÔÔòÏà·´£©¡£
Ö÷Òª¹Û²ìÖ¸±ê£ºEH×éºÍÕý³£¶ÔÕÕ×éÊÜÊÔÕßµÄÒ»°ãÇé¿ö¡¢HGF»ùÒòC57488A¸÷»ùÒòÐͺ͵Èλ»ùÒòƵÂÊ·Ö²¼¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷Õß²ÉÓÃSPSS 14.0Èí¼þÍê³Éͳ¼Æ´¦Àí£¬Êý¾ÝÒÔ_x¡Às±íʾ£»Á½×é¶ÔÏó»ùÒòÐͺ͵Èλ»ùÒòƵÂʱȽϡ¢»ùÒòÐÍ·Ö²¼ÓëHardy-WeinbergƽºâµÄ·ûºÏ³Ì¶ÈÓæÖ2¼ìÑé»òFisherÈ·ÇиÅÂÊ·¨£»Á½×é¼ä¾ùÊý±È½Ï²ÉÓÃt¼ìÑé¡£P < 0.05Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒå¡£
2 ½á¹û
2.1 ²ÎÓëÕßÊýÁ¿·ÖÎö ÄÉÈëEH»¼Õß107ÀýºÍ½¡¿µÈË110Ãû£¬¾ù½øÈë½á¹û·ÖÎö£¬ÎÞÍÑÂä¡£
2.2 EH×éºÍÕý³£¶ÔÕÕ×éÊÜÊÔÕßÁÙ´²Ö¸±ê±È½Ï ¼û±í1¡£
Á½×é¼ä¸÷Ö¸±ê¾ùÎÞÏÔÖøÐÔ²îÒ죨P > 0.05£©¡£Òò²¿·Ö»¼ÕßÓзþÓýµÑ¹Ò©£¬Î´×öÁ½×é¼äµÄѪѹ±È½Ï¡£
2.3 »ùÒòÐ͵ÄÅж¨ Èçͼ2Ëùʾ£¬1¡¢3¡¢5Ó¾µÀΪPCRÖмÓP1-CÒýÎïµÄµçÓ¾½á¹û£»2¡¢4¡¢6Ó¾µÀΪ¼ÓP1-AÒýÎïµçÓ¾½á¹û¡£¸ù¾ÝǰÊöµÄSASP-PCRÔÀí£¬Ôò1¡¢2Ó¾µÀ×éΪCA»ùÒòÐÍ£»3¡¢4×éΪAA»ùÒòÐÍ£»5¡¢6×éΪCC»ùÒòÐÍ¡£
2.4 HGF»ùÒòC57488A»ùÒò¶à̬ÐÔ·Ö²¼ ËùÓÐÊÜÊÔ¶ÔÏó¹²217Àý£¬»ùÒòÐÍ·Ö±ðΪCC140Àý¡¢CA61Àý¡¢AA16Àý£¬ÆäƵÂÊ·Ö±ðΪ0.645¡¢0.281¡¢0.074£¬C¡¢AµÈλ»ùÒòƵÂÊΪ0.786¡¢0.214¡£¾¼ìÑ飬Æä»ùÒòÐÍ·Ö²¼·ûºÏHardy-Weinbergƽºâ(P > 0.05)£¬ËµÃ÷´ïµ½ÒÅ´«Æ½ºâ£¬¾ßÓÐȺÌå´ú±íÐÔ¡£
2.5 EH×éºÍÕý³£¶ÔÕÕ×éHGF»ùÒòC57488A¸÷»ùÒòÐͺ͵Èλ»ùÒòƵÂÊ·Ö²¼ ¼û±í2¡£
3 ÌÖÂÛ
ÄÚÆ¤¹¦Äܲ»È«ÔÚEH·¢²¡ÖаçÑÝÖØÒª½ÇÉ«¡£¹úÄÚÍâ¹ØÓÚHGFÓëÄÚÆ¤Ï¸°û¹¦ÄܵÄÑо¿ÆÄ¶à¡£½¯ÒÝ·çµÈ[11]Ñо¿·¢ÏÖHGFÃ÷ÏÔ´Ù½øÌåÍâÅàÑøµÄѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³ºÍÒÆÐС£YamamotoµÈ[12]Ñо¿·¢ÏÖ£¬È±ÑõÄÜÓÕ·¢ÈËÖ÷¶¯ÂöÄÚÆ¤Ï¸°û·¢ÉúµòÍö£¬¼ÓÈëHGFºóÄÚÆ¤Ï¸°ûµòÍöÃ÷ÏÔÊܵ½ÒÖÖÆ¡£»¹ÓÐÑо¿½á¹û[13]ÓëÉÏÊöÀàËÆ¡£ÉÏÊöÑо¿ÏÔʾHGFÊÇÄÚÆ¤Ï¸°ûÌØÒìÐÔÉú³¤Òò×Ó£¬´Ù½øÄÚÆ¤Ï¸°ûÔöÖ³£¬ÒÖÖÆÄÚÆ¤Ï¸°ûµòÍö£¬ÌáʾHGFÔÚ¸ßѪѹÄÚÆ¤Ï¸°ûËðÉË·½Ãæ¿ÉÄÜÆðµ½Ò»¶¨µÄÐÞ¸´±£»¤×÷Óá£
ÔÚѪHGFˮƽÓë¸ßѪѹÁÙ´²Ñо¿·½Ãæ²»¾¡Ò»Ö£¬ÉÙÊýѧÕß±¨µÀѪHGFˮƽÓë¸ßѪѹÎÞÏà¹ØÐÔ[14-15]£¬¶ø¶àÊýÑо¿ÏÔÏÖÁ½ÕßÖ®¼äÓÐÏà¹ØÐÔ£¬ÈçNakamuraµÈ[9]·¢ÏÖ£¬ HGFˮƽÓëÊÕËõѹ¡¢ÊæÕÅѹ³ÊÕýÏà¹ØÐÔ£¬ÑªÑ¹Ô½¸ß£¬HGFˮƽԽ¸ß¡£ÔÚ±ÊÕß[16]µÄǰÆÚÑо¿Öз¢ÏÖѪHGFˮƽÔÚ3¼¶¸ßѪѹÖÐ×î¸ß£¬ÔÚ2¼¶ºÍ1¼¶¸ßѪѹÖиßÓÚÕý³£¶ÔÕÕ×é¡£³Â½¨Ó¢µÈ[17]Ò²¾Í¸ßѪѹÓëHGFˮƽ¡¢ÄÚÆ¤Ï¸°ûÒò×ÓÄÚÆ¤ËØ1¡¢Ñª¹Ü½ôÕÅËØ¢ò×öÒ»Ñо¿£¬½á¹û·¢ÏÖ1¡¢2¼¶¸ßѪѹ»¼ÕßѪHGF¡¢ÄÚÆ¤ËØ1¡¢Ñª¹Ü½ôÕÅËØ¢òˮƽÃ÷ÏÔ¸ßÓÚÕý³£¶ÔÕÕ×飬ÇÒÓëÆ½¾ù¶¯ÂöѹÕýÏà¹Ø¡£ÕâЩÑо¿½á¹ûÌáʾHGF¿ÉÄÜ·´Ó³Á˸ßѪѹѪ¹ÜÄÚÆ¤¹¦Äܲ»È«µÄÑÏÖØ³Ì¶È¡£¶øÑªHGFˮƽÊÜ»ùÒòµ÷¿Ø£¬¹Ê¶ø±àÂëHGF»ùÒòµÄ¶à̬ÐÔ¿ÉÄÜÓëEH·¢²¡µÄÒÅ´«»úÖÆÏà¹Ø¡£
ÈËHGF»ùÒòλÓÚµÚ7ºÅȾɫÌ峤±Û7q11.2~21£¬È«³¤70 kb£¬°üÀ¨18¸öÍâÏÔ×ÓºÍ17¸öÄÚº¬×Ó[18]¡£¹úÄÚÍâ¹ØÓÚHGF»ùÒò¶à̬ÐÔÑо¿ÉÐÉÙ£¬MotoneµÈ[19]Ñо¿ÁËÈÕ±¾ÈËȺHGF»ùÒòC57488AµÄ¶à̬ÐÔÓëEHµÄ¹ØÏµ£¬°üÀ¨278ÀýEH»¼ÕߺÍ376Ãû¶ÔÕÕ×飬½á¹ûÏÔʾEH·¢²¡ÂÊÔÚCC»ùÒòÐÍÃ÷ÏÔ¸ßÓÚAµÈλ»ùÒò£¬ÔÚÅ®ÐÔ¡¢ÏûÊÝÌåÐÎÕßÖÐÓÈÆäÏÔÖø¡£TakiuchiµÈ[20]Ò²½øÐÐÁËÀàËÆÑо¿£¬½á¹ûÏÔʾHGF»ùÒòµÄC-1652T¡¢T43839A¡¢T44222C»ùÒòÐÍ¡¢µÈλ»ùÒòƵÂʾùÓë¸ßѪѹÎÞÏà¹ØÐÔ¡£
±¾ÊÔÑé¾ÍºÏ·ÊµØÇøºº×åEH×黼ÕߺÍÕý³£¶ÔÕÕ×éµÄHGF»ùÒòC57488A½øÐжà̬ÐÔ·ÖÎö£¬½á¹û±íÃ÷CC»ùÒòÐÍÆµÂÊ¡¢CµÈλ»ùÒòƵÂÊEH×é¾ù¸ßÓÚÕý³£¶ÔÕÕ×飬²îÒìÏÔÖø(P < 0.01£¬P < 0.05)¡£ÆäÖÐÁ½Õ߯µÂÊÔÚÓмÒ×åÊ·ÕßÒà¸ßÓÚÎÞ¼Ò×åÊ·Õߣ¬µ«²îÒìÎÞÏÔÖøÐÔ(P > 0.05)¡£ËùÓÐÊÜÊÔ¶ÔÏó»ùÒò·ûºÏHardy-WeinbergÒÅ´«Æ½ºâ·¨Ôò£¬Óë¹úÍâMotoneµÈ[19]±¨µÀÒ»Ö¡£µ«MotoneµÈ¶ÔÈÕ±¾ÈËȺµÄÑо¿½á¹ûÏÔʾÆäHGF»ùÒòC57488AµÄCC»ùÒòÐÍÂÔ¸ßÓںϷʺº×åÈËȺ£¬ÌáʾÆä»ùÒò¶à̬ÐÔ·Ö²¼¾ßÓÐÒ»¶¨µÄÖÖ×å²îÒì¡£
EHÊÇÒ»ÖÖ»·¾³ÒòËØºÍÒÅ´«ÒòËØ¹²Í¬×÷Óõļ²²¡£¬³ýÁËÊܵØÇøºÍÖÖ×å²îÒìµÄÓ°ÏìÍ⣬»¹ÊÜÊÜÊÔÕßµÄÄêÁä¡¢ÐÔ±ð¡¢ÌåÖÊÁ¿Ö¸ÊýµÈÒòËØµÄÓ°Ïì¡£±¾ÊÔÑé±£³ÖEH×éºÍÕý³£¶ÔÕÕ×éÉÏÊöÒòËØ¼°Ò»°ãÁÙ´²Éú»¯Ö¸±êÆëͬ£¬¾¡Á¿±ÜÃâÆä¶ÔÊÔÑé½á¹ûµÄÓ°Ïì¡£½á¹ûÌáʾ£¬ºÏ·ÊµØÇøºº×åÈËȺHGF»ùÒòC57488A¶à̬ÐÔÓëEHµÄ·¢²¡¿ÉÄÜÓÐÏà¹ØÐÔ£¬²»ÂÛÊÇ·ñÓиßѪѹ¼Ò×åÊ·£¬Ð¯´øCC»ùÒòÐÍ¡¢CµÈλ»ùÒò¾ùΪ¸ßѪѹÒ׸ÐÒòËØ¡£
4 ²Î¿¼ÎÄÏ×
1 Hanis CL£¬Sing CF£¬Clarke WR£¬et al. Multivariate models for human genetic analysis£ºaggregation£¬coaggregation£¬and tracking of systolic blood pressure and weight. Am J Hum Genet 1983;35(6):1196-1210
2 Matsubara M. Genetic determination of human essential hypertension. Tohoku J Exp Med 2000;192(1):19-33
3 Liu TB,Shang HP,Zhang KX,et al. Association of angiotensin I converting enzyme 2 gene polymorphism with essential hypertension in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22(5):569-571
4 Liljedahl U,Kahan T,Malmqvist K,et al. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens 2004;22(12):2321-2328
5 Su X,Lee L,Li X,et al. Association between angiotensinogen£¬angiotensin II receptor genes£¬and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007;115(6): 725-732
6 Ma HX£¬Xie ZX£¬Niu YH£¬et al. Single nucleotide polymorphisms in NOS3 A-922G,T-786C and G894T:a correlation study of the distribution of their allelic combinations with hypertension in chinese Han population. Yi Chuan 2006;28(1):3-10
7 Cui J,Melista E,Chazaro I,et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens 2005;23(1):55-62
8 Komai N£¬Ohishi M£¬Morishita R£¬et al. Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients. Am J Hypertens 2002;15(6)£º499-506
9 Nakamura S£¬Moriguchi A£¬Morishita R£¬et al. A novel vascular modulator£¬hepatocyte growth factor (HGF)£¬as a potential index of the severity of hypertension. Biochem Biophys Res Commun 1998£»242(1)£º238-243
10 Ma HX,Niu YH,Li ZY,et al. Shengwu Jishu 2005;15(1):15-18
ÂíºñÑ«,Å£ÓÀºì,ÀîÕÂÓÂ,µÈ.µÈλ»ùÒòÌØÒìÐÔÒýÎïPCR¼¼Êõ¼°ÆäÓ¦ÓÃÑо¿[J].ÉúÎï¼¼Êõ,2005,15(1):15-18
11 Jiang YF,Lin XY,Chen SH,et al. Jiefangjun Yixue Zazhi 2003;28(1): 443-444,473
½¯ÒÝ·ç,ÁÖÏþÔÅ,³ÂË«ºì,µÈ.¸Îϸ°ûÉú³¤Òò×Ó¶ÔÐļ¡Ï¸°û¼°Ñª¹Üƽ»¬¼¡Ï¸°û¡¢Ñª¹ÜÄÚÆ¤Ï¸°ûÉú³¤Òò×Ó·ÖÃÚµÄ×÷ÓÃ[J].½â·Å¾üҽѧÔÓÖ¾,2003,28(1):443-444,473
12 Yamamoto K£¬Morishita R£¬Hayashi S£¬et al. Contribution of Bcl-2, but not Bcl-xL and Bax£¬to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 2001£»37(5):1341-1348
13 Wang BN£¬Hu ZP£¬Chen DN£¬et al. Zhonghua Gaoxueya Zazhi 2007;15(3):219-222
Íõ°îÄþ,ºúÔóƽ,³Â´óÄê,µÈ.¸ßѪѹ»¼ÕßѪ¸Îϸ°ûÉú³¤Òò×ÓÓëѪ¹ÜÄÚÆ¤¹¦ÄܵĹØÏµ¼°¸ÉÔ¤Ñо¿[J].Öлª¸ßѪѹÔÓÖ¾,2007,15(3):219-222
14 van Belle E,Witzenbichler B,Chen D,et al. Potentiated angiogenic effect of scatter factor / hepatocyte growth factor via induction of vascular endothelial growth factor:the case for paracrine amplification of angiogenesis. Circulation 1998;97(4):381-390
15 Nishimura M£¬Ushiyama M£¬Nanbu A£¬et al. Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens 1997; 15(10):1137-1142
16 Wang YM£¬Wu ZG£¬Huang Z£¬et al. Dier Junyi Daxue Xuebao 2001;22(2)£º138-139
Íõӽ÷,Îâ×Ú¹ó,»Æ×ô,µÈ.¸Îϸ°ûÉú³¤Òò×ÓˮƽÓë¹Ú×´¶¯ÂöÖàÑùÓ²»¯¼°¸ßѪѹ²¡µÄ¹ØÏµ[J].µÚ¶þ¾üÒ½´óѧѧ±¨,2001,22(2):138-139
17 Chen JY,Chen XY,Huang SA,et al. Zhongguo Xunhuan Zazhi 2004;19(4):283-285
³Â½¨Ó¢,³ÂÏþÓÚ,»ÆÊ¯°²,µÈ.Ô·¢ÐÔ¸ßѪѹ»¼Õ߸Îϸ°ûÉú³¤Òò×Ó¡¢Ñª¹Ü½ôÕÅËØ¢ò¡¢ÄÚÆ¤Ëصı仯¼°±½ÄÇÆÕÀûµÄ¸ÉÔ¤×÷ÓÃ[J].ÖйúÑ»·ÔÓÖ¾,2004,19(4):283-285
18 Weidner KM£¬Arakaki N£¬Hartmann G£¬et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 1991;88(16):7001-7005
19 Motone M,Katsuya T,Ishikawa K,et al. Association between Hepatocyte Growth Factor Gene Polymorphism and Essential Hypertension. Hypertens Res 2004;27(4):247-251
20 Takiuchi S,Mannami T,Miyata T,et al. Identification of 21 single nucleotide polymorphisms in human hepatocyte growth factor gene and association with blood pressure and carotid atherosclerosis in the Japanese population. Atherosclerosis 2004;173(2):301-307
|